The potential population health impact of treating REDUCE-IT eligible US adults with Icosapent Ethyl. (Record no. 435)

MARC details
000 -LEADER
fixed length control field 03330nam a22003737a 4500
008 - FIXED-LENGTH DATA ELEMENTS--GENERAL INFORMATION
fixed length control field 220706s20222022 xxu||||| |||| 00| 0 eng d
022 ## - INTERNATIONAL STANDARD SERIAL NUMBER
International Standard Serial Number 2666-6677
024 ## - OTHER STANDARD IDENTIFIER
Standard number or code 10.1016/j.ajpc.2022.100345 [doi]
024 ## - OTHER STANDARD IDENTIFIER
Standard number or code PMC9097618 [pmc]
024 ## - OTHER STANDARD IDENTIFIER
Standard number or code S2666-6677(22)00029-0 [pii]
040 ## - CATALOGING SOURCE
Original cataloging agency Ovid MEDLINE(R)
099 ## - LOCAL FREE-TEXT CALL NUMBER (OCLC)
PMID 35574517
245 ## - TITLE STATEMENT
Title The potential population health impact of treating REDUCE-IT eligible US adults with Icosapent Ethyl.
251 ## - Source
Source American Journal Of Preventive Cardiology. 10:100345, 2022 Jun.
252 ## - Abbreviated Source
Abbreviated source Am J Prev Cardiol. 10:100345, 2022 Jun.
253 ## - Journal Name
Journal name American journal of preventive cardiology
260 ## - PUBLICATION, DISTRIBUTION, ETC.
Year 2022
260 ## - PUBLICATION, DISTRIBUTION, ETC.
Manufacturer FY2022
260 ## - PUBLICATION, DISTRIBUTION, ETC.
Publication date 2022 Jun
265 ## - SOURCE FOR ACQUISITION/SUBSCRIPTION ADDRESS [OBSOLETE]
Publication status epublish
265 ## - SOURCE FOR ACQUISITION/SUBSCRIPTION ADDRESS [OBSOLETE]
Medline status PubMed-not-MEDLINE
266 ## - Date added to catalog
Date added to catalog 2022-07-06
520 ## - SUMMARY, ETC.
Abstract Conclusions: Treating all REDUCE-IT eligible US adults has substantial medication costs but could prevent a substantial number of ASCVD events and associated direct costs. Indirect cost savings by preventing events could outweigh much of the incurred direct costs. Copyright © 2022 The Author(s).
520 ## - SUMMARY, ETC.
Abstract Methods: We derived REDUCE-IT eligible cohorts in (1) the National Health and Nutrition Examination Surveys (NHANES) 2009-2014 and (2) the Optum Research Database (ORD). Population sizes were obtained from NHANES and observed first event rates (composite of cardiovascular death, nonfatal myocardial infarction, nonfatal stroke, unstable angina requiring hospitalization, or coronary revascularization) were estimated from the ORD. Hazard ratios from REDUCE-IT USA estimated events prevented with IPE therapy. The National Inpatient Sample estimated event costs (facility and professional) and daily IPE treatment cost was approximated at
-- .59.
520 ## - SUMMARY, ETC.
Abstract Objective: To explore the population health impact of treating all US adults eligible for the Reduction of Cardiovascular Events with Icosapent Ethyl-Intervention Trial (REDUCE-IT) with icosapent ethyl (IPE), we estimated (1) the number of ASCVD events and healthcare costs that could be prevented; and (2) medication costs.
520 ## - SUMMARY, ETC.
Abstract Results: We estimate 3.6 million US adults to be REDUCE-IT eligible, and the observed five-year first event rate without IPE of 19.0% (95% confidence interval [CI] 16.6%-19.5%) could be lowered to 13.1% (95% CI 12.8%-13.5%) with five years of IPE treatment, preventing 212,000 (uncertainty range 163,000-262,000) events. We projected the annual IPE treatment cost for all eligible persons to be
Linkage .0 billion (95% CI
-- .7-
-- .5 billion), but saving
-- .8 billion annually due to first events prevented (net annual cost
-- .3 billion). The total five-year event rate (first and recurrent) could be reduced from 42.5% (95% CI 39.6%-45.4%) to 28.9% (95% CI 26.9-30.9%) with five years of IPE therapy, preventing 490,000 (uncertainty range 370,000-609,000) events (net annual cost
Source .6 billion).
546 ## - LANGUAGE NOTE
Language note English
651 ## - SUBJECT ADDED ENTRY--GEOGRAPHIC NAME
Institution MedStar Health Research Institute
657 ## - INDEX TERM--FUNCTION
Medline publication type Journal Article
700 ## - ADDED ENTRY--PERSONAL NAME
Local Authors Weintraub, William S
790 ## - Authors
All authors Abrahamson D, Andrade KE, Bhatt DL, Bress AP, Derington CG, Fan W, Herrick JS, Jiao L, Johnson J, Philip S, Weintraub WS, Wong ND
856 ## - ELECTRONIC LOCATION AND ACCESS
DOI <a href="https://dx.doi.org/10.1016/j.ajpc.2022.100345">https://dx.doi.org/10.1016/j.ajpc.2022.100345</a>
Public note https://dx.doi.org/10.1016/j.ajpc.2022.100345
942 ## - ADDED ENTRY ELEMENTS (KOHA)
Koha item type Journal Article
Item type description Article
Holdings
Withdrawn status Lost status Damaged status Not for loan Collection Home library Current library Date acquired Total Checkouts Full call number Barcode Date last seen Price effective from Koha item type
          MedStar Authors Catalog MedStar Authors Catalog 07/06/2022   35574517 35574517 07/06/2022 07/06/2022 Journal Article

Powered by Koha